Skip to main content
SpringerLink
Log in

Pharmacokinetics of intravenous omeprazole in children

  • Original
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

This study was undertaken to define the pharmacokinetics of omeprazole in children and included 13 patients, heterogenous in terms of age (0.3 to 19 years), underlying disease and biological constants, indication of omeprazole administration and associated therapy. The dose administered ranged from 36.9 to 139 mg·1.73 m−2.

The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 1·kg−1·h−1; volume of distribution, 0.45 1·kg−1; elimination half life 0.86 h; but were highly variable between individuals. Dosage, differences in hepatic and renal function and associated therapy may contribute to inter-individual variability.

Within the range of doses administered, the pharmacokinetic parameters were similar to those reported in adults. The drug has been well tolerated in all children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I (1990) The pharmacokinetics of omeprazole in humans — a study of single intravenous and oral doses. Ther Drug Monit 12: 163–172

    Google Scholar 

  2. Andersson T, Cederberg C, Regardh CG, Skanberg I (1990) Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 39: 195–197

    Google Scholar 

  3. Cederberg C, Andersson T, Skanberg I (1989). Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 166 [Suppl]: 33–40

    Google Scholar 

  4. Jansen BMJ, Lundborg P, Baak LC, Greve J, Ohman M, Stover Rohss K, Lamers CBHW (1988) Effect of single and repeated intravenous doses of omeprazole on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Gut 29: 75–80

    Google Scholar 

  5. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin-stimulated acid secretion in man. Gut 24: 270–276

    Google Scholar 

  6. Lind T, Moore M, Olbe L (1986) Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients. Digestion 34: 78–86

    Google Scholar 

  7. Walt RP, Reynolds JR, Langman MJS, Smart HL, Kitchingman G, Somerville KW, Hawke CJ (1985) Intravenous omeprazole rapidly raises intragastric pH. Gut 26: 902–906

    Google Scholar 

  8. Brunner G, Chang J (1990) Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion 45: 217–225

    Google Scholar 

  9. Bardhan KD, Bianchi-Porro G, Bose K, Hincliffe RFC, Lazzaroni M (1986) A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcer. J Clin Gastroenterol 8: 408–413

    Google Scholar 

  10. Dehn TCB, Shepardh HA, Colin-Jones D, Kettlewell MGW, Carrol NJ (1990) Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qds) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring Gut 31: 509–513

    Google Scholar 

  11. Klinkenberg-Knol ED, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW (1987) Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet I: 349–351

    Google Scholar 

  12. Lamers CBHW, Lind T, Moberg S, Jansen JBMJ, Olbe L (1984) Omeprazole in Zollinger-Ellison syndromes. N Engl J Med 310: 758–761

    Google Scholar 

  13. Kato S, Shibuya H, Hayashi Y, Tseng SW, Nakagawa H, Ohi R (1992) Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer (Case Report). J Pediatr Gastroenterol Nutr 15: 184–188

    Google Scholar 

  14. De Giacomo C, Fiocca R, Villani L, Licardi G, Scotta MS, Solcia E (1990) Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpeptidogenemia I in an infant. J Pediatr 117: 989–93

    Google Scholar 

  15. Frits Nelis G, Westerveld BD (1990) Treatment of resistant reflux oesophagitis in children with omeprazole. Eur J Gastrenterol Hepatol 2: 215–217

    Google Scholar 

  16. Gunasekaran TS, Hassall EG (1993) Efficacy and safety of omeprazole for severe gastro-oesophageal reflux in children. J Pediatr 123: 148–154

    Google Scholar 

  17. Amantea MA, Narang PK (1988) Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography. J Chromatogr 426: 216–222.

    Google Scholar 

  18. Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I (1985) Pharmacokinetics and metabolism of omeprazole in animals and man — an overview. Scand J Gastroenterol 108: 79–94

    Google Scholar 

  19. Regardh CG (1986) Pharmacokinetics and metabolism of omeprazole in man. A survey of available results. Scand J Gastroenterol 118: 99–104

    Google Scholar 

  20. Andersson T, Regardh CG, Dalh-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415–416

    Google Scholar 

  21. Curi-Pedrosa R, Pichard L, Bonfils C, Jacqz Aigrain E, Guengerich FP, Maurel P (1993). Major implication of cytochrome P450 3A4 in the oxidative metabolism of antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Fifth European ISSX Meeting, 26–29 September, Tours, France

  22. Andersson J, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521–530.

    Google Scholar 

  23. Andersson T, Regardh CG (1990) Pharmacokinetics of omeprazole and metabolites following single intravenous and oral doses of 40 and 80 mg. Drug Invest 4: 255–263

    Google Scholar 

  24. McKee RF, MacGilchrist AJ, Garden OJ, Forrest AH, Carter DC (1988) The antisecretory effect and pharmacokinetics of omeprazole in chronic liver disease. Aliment Pharmacol Ther 2: 429–438

    Google Scholar 

  25. Cederberg C, Thomson ABR, Mahachai V, Westin JA, Kirdeikis P, Fisher D, Zuk L, Marriage B (1992) Effect of intravenous and oral omeprazole on 24 h intragastric acidity in duodenal ulcer patients. Gastroenterol 103: 913–918

    Google Scholar 

  26. Naesdal J, Andersson T, Bodemar G, Larsson R, Regardh CG, Skanberg I, Walan A (1986) Pharmacokinetics of 14C-omeprazole in patients with impaired renal function. Clin Pharmacol Ther 40: 344–351

    Google Scholar 

  27. Roggo A, Filippini L, Colombi A (1990) The effect of hemodialysis on omeprazole: plasma concentrations in the anuric patient: a case report. Int J Clin Pharmacol Ther Toxicol 28: 115–117

    Google Scholar 

  28. Blohmé I, Idstrom JP, Andersson T (1993) A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 35: 156–160

    Google Scholar 

  29. Andersson T (1991). Omeprazole drug interaction studies. Clin Pharmacokinet 21: 195–212

    Google Scholar 

  30. Gugler R, Jensen JC (1985) Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235–1241

    Google Scholar 

  31. Gugler R, Jensen JC (1987) Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 33: 133–137

    Google Scholar 

  32. Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S (1987) Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 33: 369–373

    Google Scholar 

  33. Bannister J, Noble DW, Lamont M, Scott DB (1990) Lack of omeprazole effect on the disposition of lignocaine and its active metabolite in healthy subjects (abstract). World Congress of Gastroenterology, Sydney, Australia

    Google Scholar 

  34. Ching MS, Elliot SL, Murdock RT, Stead CK, Devenish-Meares SE, Smallwood RA (1990) Quinidine and 3-hydroxy quinidine pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Abstract PD1157, Abstracts II, World Congress of Gastroenterology, Sydney, Australia

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Hôpital Robert Debré, 48 Boulevard Sérurier, F-75019, Paris, France

    E. Jacqz-Aigrain & J. Andre

  2. Department of Gastro-enterology, Hôpital Robert Debré, Paris, France

    M. Bellaich, C. Faure & J. Navarro

  3. Department of Haemato-Immunology, Hôpital Robert Debré, Paris, France

    P. Rohrlich

  4. Department of Nephrology, Hôpital Robert Debré, Paris, France

    V. Baudouin

Authors
  1. E. Jacqz-Aigrain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Andre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bellaich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Faure
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Rohrlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Baudouin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacqz-Aigrain, E., Andre, J., Bellaich, M. et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 47, 181–185 (1994). https://doi.org/10.1007/BF00194970

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194970

Key words

Search

Navigation